A novel mannoside-glycocluster adjuvant: Compared in vitro to CpG ODN and MPL and tested in vivo in mouse asthma model



: Makinen K, Mukherjee C, Leino M, Panchadhayee R, Lehto M, Wolff H, Alenius H, Leino R, Savolainen J

Publisher: ELSEVIER DOYMA SL

: 2016

: Allergologia et Immunopathologia

: ALLERGOLOGIA ET IMMUNOPATHOLOGIA

: ALLERGOL IMMUNOPATH

: 44

: 1

: 9

: 17

: 9

: 0301-0546

DOI: https://doi.org/10.1016/j.aller.2015.04.008(external)


Conclusions: TADM suppresses the birch allergen induced Th2-type cytokine responses in allergic subjects more efficiently than the two other adjuvants, MPL and CpG ODN. TADM is immunomodulatory also in vivo and decreases the IgE levels and increases the IFN-gamma responses in a murine model. These results suggest that TADM may be a promising candidate for novel adjuvants in immunotherapy. (C) 2014 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.




Last updated on 2024-26-11 at 15:10